RxDoctor Payments Data

Tze-Ming Chen, MD

Pulmonary Disease · San Francisco, CANPI 1215092705

Payments from drug & device makers

$23,721in general payments, 2019–2025

Across 23 payments — averaging $1031.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$16K
  • Gyrus ACMI, Inc.$5K
  • Spiration, Inc.$2K
  • Pfizer$500
  • Electromed, Inc.$67
  • Pulmonx Corporation$56
  • plus $139 from 6 others

What the payments were for

  • Consulting fees$15,97595%
  • Speaking & faculty fees$5003%
  • Food & beverage$2622%

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$23,721 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$43,254
Medicare patients
92
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →